P17. Inhibition of immunoglobulin production by 1,25 (OH)2D3

Williams, M. H.; Bhalla, AK; Lydyard, PM

doi:10.1016/8756-3282(89)90041-0

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The actions or omissions of one party may indeed be the nearest cause to the damage in time and space, yet it is still legitimate to seek a contribution from co-defendants whose negligence also led to the occurrence of the damage. 103 This entitlement exists in statute; 104 a modified power also exists for the insurer of a self-driving vehicle to recover the costs of a claim award which has already been paid to the claimant. 105 In this sense, the insurer acts as a centralised claims administrator but can also investigate specific incidents in more depth.…”

Section: Risk Pooling In England and Wales: Proposals For Reformmentioning

confidence: 99%

Artificial intelligence in clinical decision-making: Rethinking liability

Smith

Fotheringham

2020

Medical Law International

View full text Add to dashboard Cite

This article theorises, within the context of the law of England and Wales, the potential outcomes in negligence claims against clinicians and software development companies (SDCs) by patients injured due to AI system (AIS) use with human clinical supervision. Currently, a clinician will likely shoulder liability via a negligence claim for allowing defects in an AIS’s outputs to reach patients. We question if this is ‘fair, just and reasonable’ to clinical users: we argue that a duty of care to patients ought to be recognised on the part of SDCs as well as clinicians. As an alternative to negligence claims, we propose ‘risk pooling’ which utilises insurance. Here, a fairer construct of shared responsibility for AIS use could be created between the clinician and the SDC; thus, allowing a rapid mechanism of compensation to injured patients via insurance.

show abstract

Section: Risk Pooling In England and Wales: Proposals For Reformmentioning

confidence: 99%

Artificial intelligence in clinical decision-making: Rethinking liability

Smith

Fotheringham

2020

Medical Law International

View full text Add to dashboard Cite

show abstract

Hydrogels in Biomedical Applications

1980

View full text Add to dashboard Cite

The nature of hydrogel polymers is described together with the range of biomedical applications in which their use has been suggested or described in the literature. The field of contact lens materials has provided the greatest variety of synthetic hydrogels and the material requirements for extended wear lenses present problems that are typical of those encountered in biomedical applications in general. The patient literature relating to contact lenses is reviewed and the development of the composition of hydrogel materials is thereby traced and compared with the range of lens materials currently available. In contrast the most commonly encountered, in fact almost the sole, hydrogel material in the literature relating to those areas more conventionally regarded as biomedical, is poly(2‐hydroxeythyl methacrylate) or polyHEMA. The use of this and related hydrogels in various applications including prostheses, ocular surgery, sature coatings, artificial internal organs and drug delivery systems is reviewed.

show abstract

P17. Inhibition of immunoglobulin production by 1,25 (OH)2D3

Cited by 2 publications

References 0 publications

Artificial intelligence in clinical decision-making: Rethinking liability

Artificial intelligence in clinical decision-making: Rethinking liability

Hydrogels in Biomedical Applications

Contact Info

Product

Resources

About